Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | GC, CCO & Corporate Secretary | June 15, 2018 | June 19, 2018 |
| GELESIS HOLDINGS, INC.GLS · Entity 109516 | General Counsel | May 06, 2022 | May 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2028-06-14 | Direct | 25,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter.
GELESIS HOLDINGS, INC.
Report date May 06, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 256,437 |
Ending reported balance
After 2022-05-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-06 · Grant · Acquired 22,732 · Balance 22,732 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2: These RSUs vest in full on February 7, 2023, subject to the reporting person's continued service at such time. Row 2 · 2022-05-06 · Grant · Acquired 233,705 · Balance 256,437 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F3: 25% of these RSUs shall vest on April 1, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2032-03-03 | Direct | 233,705 |
Reported balance
After 2022-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-06 · Grant · Acquired 233,705 · Balance 233,705 F4: 25% of the shares underlying this option shall vest and become exercisable on March 4, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2: These RSUs vest in full on February 7, 2023, subject to the reporting person's continued service at such time.
F3: 25% of these RSUs shall vest on April 1, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
F4: 25% of the shares underlying this option shall vest and become exercisable on March 4, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2022 Filed May 9, 2022 16:16 UTC | GELESIS HOLDINGS, INC. GLS · Entity 109516 | GrantStock Option (Right to Buy) · Derivative | 233,705 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001104659-22-057525 · tm2214815-3_4seq1.xml · derivative · entry 3 Abraham David · CIK 0001676903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,705 Underlying: Common Stock · 233,705 shares Expires 2032-03-03 F4 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 4, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 06, 2022 Filed May 9, 2022 16:16 UTC | GELESIS HOLDINGS, INC. GLS · Entity 109516 | GrantCommon Stock | 233,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-057525 · tm2214815-3_4seq1.xml · nonDerivative · entry 2 Abraham David · CIK 0001676903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,437 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F3 · shares: 25% of these RSUs shall vest on April 1, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. F1 · price: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. Read SEC document |
| May 06, 2022 Filed May 9, 2022 16:16 UTC | GELESIS HOLDINGS, INC. GLS · Entity 109516 | GrantCommon Stock | 22,732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-057525 · tm2214815-3_4seq1.xml · nonDerivative · entry 1 Abraham David · CIK 0001676903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,732 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2 · shares: These RSUs vest in full on February 7, 2023, subject to the reporting person's continued service at such time. F1 · price: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:06 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000679 · doc4_5478.xml · derivative · entry 1 Abraham David · CIK 0001676903 · GC, CCO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 02:58 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 5,405 | $9.25 | $49,996.25 |
DisclosureSEC source: 0001638599-17-001136 · doc4_5077.xml · nonDerivative · entry 1 Abraham David · CIK 0001676903 · GC, CCO & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,405 Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.33 | $0.00 |
DisclosureSEC source: 0001638599-17-000697 · doc4_4849.xml · derivative · entry 1 Abraham David · CIK 0001676903 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 19:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,280 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-16-163717 · a4.xml · derivative · entry 3 Abraham David · CIK 0001676903 · CCO, Gen.Counsel, Corp.Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 Underlying: Common Stock · 12,280 shares Expires 2019-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These securities are fully vested. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 19:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 14,844 | $18.00 | $267,192.00 |
DisclosureSEC source: 0001104659-16-163717 · a4.xml · nonDerivative · entry 2 Abraham David · CIK 0001676903 · CCO, Gen.Counsel, Corp.Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 19:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 12,280 | $0.47 | $5,771.60 |
DisclosureSEC source: 0001104659-16-163717 · a4.xml · nonDerivative · entry 1 Abraham David · CIK 0001676903 · CCO, Gen.Counsel, Corp.Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.